Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen - Wikidata - awgldk - TriplyDB

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

http://www.wikidata.org/entity/Q35006860

about

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen Cancer pharmacogenomics: strategies and challenges Breast cancer in the personal genomics era Applications of CYP450 testing in the clinical setting Germline pharmacogenomics in oncology: decoding the patient for targeting therapy Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen Transporting antitumor drug tamoxifen and its metabolites, 4-hydroxytamoxifen and endoxifen by chitosan nanoparticles A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.BLV-CoCoMo-qPCR: a useful tool for evaluating bovine leukemia virus infection status.Giant sucking sound: can physiology fill the intellectual void left by the reductionists?American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study The Impact of CYP2D6 Genotyping on Tamoxifen Treatment CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic.Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.PharmGKB summary: tamoxifen pathway, pharmacokinetics Basic review of the cytochrome p450 system.Coprescription of tamoxifen and medications that inhibit CYP2D6.A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply Orally administered endoxifen is a new therapeutic agent for breast cancer.Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.Tamoxifen and CYP2D6: a contradiction of data.Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.Understanding and preventing drug-drug and drug-gene interactions.Global cancer research initiative Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant.Personalized medicine and cancer.Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.

P2860

Q21195205-EE106245-1F89-40E8-BDFB-5AE1A2E0A71D Q24289309-FE147ADF-4C03-4CC1-9FEE-9C760ADB1339 Q24602679-5CFEDE73-8C3F-4693-9582-28129A8EB073 Q24621760-936EAB33-621F-41F3-AC83-0DE28E77C31E Q27022557-4F5BC2E7-4118-46D8-8067-5973F01A4761 Q27026180-7645FA36-7562-40BF-824F-4E4E67D1F821 Q28488379-C2F31B42-23AC-4898-B70F-AEE20CFFCF09 Q28943542-1603B32E-1925-4318-B480-ACEE81795E0E Q30400967-3F5E8B6E-9BF4-45A6-A80C-95041328A3F5 Q31096928-F12996A9-9D64-470D-86B1-AD2C0B1C448A Q33351391-8EB9DEB7-4CC7-4C15-AFBD-298261386FB0 Q33631047-66BE2B5B-E980-4D7B-91E4-D77333606AFE Q33634928-E7EBB069-88D1-424E-A548-A7ABE057E305 Q33664433-7BAA5142-4C78-4BBF-A312-D3ACAAFCCCFB Q33704974-A32AA4D2-42B4-4FA4-8D89-CC569A6BA238 Q33781027-44DB5A2B-B85E-434A-8841-D394D050AEDC Q33855494-18733AE5-7817-46C0-9325-ECD410D18024 Q33886025-ED593781-A536-4BD7-B490-97442B46684C Q33898184-8B92CB84-A742-4E32-802F-E6B1A2DBAA4F Q33914381-BBC69AEF-6AAB-4279-AF0C-4D062C58EE0B Q33965328-B271B008-2ADD-46ED-8B2F-D34097B2A415 Q34065337-82F46D76-31A1-400B-9CCC-379942FD6DBF Q34065341-5698531F-A873-4D30-BDDD-93EA163B9893 Q34091195-75CAF7F6-1404-4D27-A442-834121DB2B6B Q34233815-0CD85DD2-EDA9-4D55-97EA-AB240377F617 Q34244463-065B2A1B-5539-4CC3-B6C0-F48CD5284277 Q34253146-BCDC1438-97B9-4316-A581-A845AB2F265E Q34253646-DB4E80CD-463F-4775-A398-A05F6A9A7329 Q34269380-1D5B5B78-3473-4881-8560-4B2E7CE7DC85 Q34307589-AF88951B-B27C-4086-AE58-AF37A5B3BAC5 Q34307873-66DBA57D-865B-4F5C-A13C-1066F12CB128 Q34315833-4443271B-6110-4DBD-B3F0-DFEFFD110B57 Q34386787-2AD4EB92-6DF4-477F-AFC6-DED4E20D867F Q34415944-DFE2A743-E359-40D0-9A76-A9BD953E5F01 Q34417827-D03027BE-9A3E-437C-B30E-141E4ACF653B Q34594697-4743CCA3-25B9-42E6-BA33-2D6B3A932EDF Q34608577-35A29949-F316-4AC1-ACB2-EB074F56C93A Q34620545-1F539E01-C6ED-4C0E-95C9-1DBE2E712D11 Q34677193-FF9D79FD-2566-4BC7-9940-CCC5445668E9 Q34736986-FDCD92C0-6656-4562-A8F3-05A978C282F3

P2860

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

http://www.wikidata.org/entity/Q35006860

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Association between CYP2D6 pol ...... cancer treated with tamoxifen

@ast

Association between CYP2D6 pol ...... cancer treated with tamoxifen

@en

type

label

Association between CYP2D6 pol ...... cancer treated with tamoxifen

@ast

Association between CYP2D6 pol ...... cancer treated with tamoxifen

@en

prefLabel

Association between CYP2D6 pol ...... cancer treated with tamoxifen

@ast

Association between CYP2D6 pol ...... cancer treated with tamoxifen

@en

P1433

Q35006860-18D7BC25-B74F-4BD8-9F5F-63E254F77565

P1476

Q35006860-BBD1830D-4559-45A6-9ABC-30B9795AFE25

P2093

Q35006860-05FFEA32-2588-430B-BC1A-507B3D74FC28

Q35006860-2C538D9B-CF19-4161-84DF-FEFA4EB2DDF5

Q35006860-2F3D2707-9AEB-4732-A9F8-7FCC262693FD

Q35006860-30F50445-8B73-43EE-BF5F-AC3FA0E2E131

Q35006860-36320EBA-D19A-474C-AA60-E9A2DE4530C7

Q35006860-37356868-F753-4786-BEC0-0EBF5E2F924F

Q35006860-3D2ACB4D-3688-4637-81EA-A34250F5479A

Q35006860-46084CE8-2E84-4055-BDEC-36306F755C09

Q35006860-53BDA4B1-7AB8-4E7A-A856-19EAE7AE528E

Q35006860-816B9E4F-0602-4DFF-898D-ADA471EAF334

P2860

Q35006860-03B3FD1F-4ED7-4895-8774-00CEC3176658

Q35006860-16EB9ECA-F271-4A49-97BF-24FCC3156548

Q35006860-26E32C4D-25CB-4492-A3B1-174432D093D2

Q35006860-328A36FA-B91D-4A79-9581-40FB5979285D

Q35006860-3854D556-C46A-492A-AA27-269464C9E2E9

Q35006860-3912791B-2A91-4438-B89C-A9A78C326459

Q35006860-3E402008-3215-453A-B961-EDB816E7C6EC

Q35006860-4A6D81E9-7C8C-4838-A4C8-9B4E50139233

Q35006860-5F967ABA-BCA1-4257-9619-CC742A4D6385

Q35006860-68C793C1-A41E-4601-A907-25E2167BF220

P304

Q35006860-ECB717E5-9D2B-4B12-A71C-DAABA52C7EA4

P31

Q35006860-64656A5A-7077-4B53-9C88-3CF97FD16D66

P356

Q35006860-89CFD05D-F971-4818-8D7F-5CB6204EC920

P407

Q35006860-EB3F9BDD-EE1B-4DA1-B992-9645AF5C0D31

P433

Q35006860-C6055F70-EBF3-48D5-8A8E-543AA057B392

P478

Q35006860-02F485F0-1DB7-4309-99A0-A6CE1C3EB914

P50

Q35006860-05EE7166-A06D-4E01-BF5F-976B92889F71

Q35006860-08263AE1-B97E-4CB3-A8F5-AF1667FD4B96

Q35006860-920AEFA1-65DF-4CC0-9F07-C284ECC349F4

Q35006860-AEC222EC-2C9B-4C1E-A64B-19CC9C042EEF

Q35006860-D85290B0-0BE0-4878-8CB6-FBF8D682ED9A

P577

Q35006860-E9FF8C38-FE76-4F8A-ABB1-06842FB64B40

P5875

Q35006860-2577D795-815A-4F8B-8057-B367DE6EEFCB

P698

Q35006860-7E26699E-B528-4D5E-BA1C-3B23EEF2C41F

P932

Q35006860-76AECD97-FF11-4E05-9A6D-86E81EBE3F4D

P356

P1433

Journal of the American Medical Association

P1476

Association between CYP2D6 pol ...... cancer treated with tamoxifen

@en

P2093

Hans Ulrich Ulmer

http://www.w3.org/2001/XMLSchema#string

Heinz Koelbl

http://www.w3.org/2001/XMLSchema#string

James N Ingle

http://www.w3.org/2001/XMLSchema#string

Julia Boländer

http://www.w3.org/2001/XMLSchema#string

Marcus Schmidt

http://www.w3.org/2001/XMLSchema#string

Mary J Kuffel

http://www.w3.org/2001/XMLSchema#string

Matthew M Ames

http://www.w3.org/2001/XMLSchema#string

Matthew P Goetz

http://www.w3.org/2001/XMLSchema#string

Matthias Schwab

http://www.w3.org/2001/XMLSchema#string

Michel Eichelbaum

http://www.w3.org/2001/XMLSchema#string

P2860

Tamoxifen: catalyst for the change to targeted therapy

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.

Inheritance and drug response.

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

P304

1429-1436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2009.1420

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

302

http://www.w3.org/2001/XMLSchema#string

P50

Richard Weinshilboum

Peter A. Fasching

Matthias W. Beckmann

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26875996

http://www.w3.org/2001/XMLSchema#string

P698

19809024

http://www.w3.org/2001/XMLSchema#string

P932

3909953

http://www.w3.org/2001/XMLSchema#string